ATE319475T1 - Microbielles wirkstoffabgabesystem - Google Patents

Microbielles wirkstoffabgabesystem

Info

Publication number
ATE319475T1
ATE319475T1 AT00982485T AT00982485T ATE319475T1 AT E319475 T1 ATE319475 T1 AT E319475T1 AT 00982485 T AT00982485 T AT 00982485T AT 00982485 T AT00982485 T AT 00982485T AT E319475 T1 ATE319475 T1 AT E319475T1
Authority
AT
Austria
Prior art keywords
proteins
allergic
allergens
subjects
microorganisms
Prior art date
Application number
AT00982485T
Other languages
German (de)
English (en)
Inventor
Michael Caplan
Original Assignee
Seer Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seer Pharmaceuticals Llc filed Critical Seer Pharmaceuticals Llc
Application granted granted Critical
Publication of ATE319475T1 publication Critical patent/ATE319475T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00982485T 2000-04-06 2000-12-06 Microbielles wirkstoffabgabesystem ATE319475T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19503500P 2000-04-06 2000-04-06
US09/731,375 US8153414B2 (en) 2000-04-06 2000-12-06 Microbial delivery system

Publications (1)

Publication Number Publication Date
ATE319475T1 true ATE319475T1 (de) 2006-03-15

Family

ID=26890647

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00982485T ATE319475T1 (de) 2000-04-06 2000-12-06 Microbielles wirkstoffabgabesystem

Country Status (11)

Country Link
US (6) US8153414B2 (enExample)
EP (1) EP1272213B1 (enExample)
JP (3) JP2004527450A (enExample)
AT (1) ATE319475T1 (enExample)
AU (2) AU2001219510B2 (enExample)
CA (1) CA2403292C (enExample)
CY (1) CY1105216T1 (enExample)
DE (1) DE60026584T2 (enExample)
DK (1) DK1272213T3 (enExample)
ES (1) ES2260078T3 (enExample)
WO (1) WO2001066136A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6698162B2 (en) * 2000-03-23 2004-03-02 Teikoku Pharma Usa, Inc. Methods of producing a terminally sterilized topical patch preparation
ES2260078T3 (es) * 2000-04-06 2006-11-01 Seer Pharmaceuticals, Llc. Sistema de administracion microbiana.
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
EP1278550A4 (en) * 2000-04-07 2004-05-12 Univ California SYNERGISTIC IMPROVEMENTS OF POLYNUCLEOTIDE VACCINE
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
US7060687B2 (en) 2001-02-07 2006-06-13 Genmont Biotechnology Co. Live vaccines for allergy treatment
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
AU2003301021C1 (en) * 2002-12-16 2010-02-18 Globelmmune, Inc. Yeast-based vaccines as immunotherapy
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US20070231796A1 (en) * 2003-09-17 2007-10-04 The Regents Of The University Of California Sensor and method for detection of a target substance
JP5234445B2 (ja) * 2004-10-05 2013-07-10 源一郎 杣 薬剤
AU2005295317B2 (en) * 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US20100034840A1 (en) * 2005-07-11 2010-02-11 David Apelian Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
CN101448848B (zh) * 2006-03-27 2013-12-04 全球免疫股份有限公司 Ras突变及其相关组合物和方法
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
JP5570819B2 (ja) 2007-02-02 2014-08-13 グローブイミューン，インコーポレイテッド 酵母を含む組成物および酵母を増殖させる方法
EP2134358A1 (en) * 2007-03-19 2009-12-23 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
ES2950396T3 (es) 2008-02-01 2023-10-09 Prota Therapeutics Pty Ltd Un método para inducir tolerancia a un alérgeno
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
EP2419126B1 (en) 2009-04-17 2018-01-10 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
WO2011008735A1 (en) * 2009-07-13 2011-01-20 Vaxgene Corporation Oral vaccines produced and administered using edible micro-organism
JP5913103B2 (ja) 2009-09-14 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
AP2013007110A0 (en) 2011-02-12 2013-09-30 Globeimmune Inc Yeast-based therapeutic for chronic hepatitis B infection
AU2012228937B2 (en) 2011-03-17 2016-11-03 Globeimmune, Inc. Yeast-Brachyury immunotherapeutic compositions
BR112013032381B1 (pt) 2011-06-14 2021-01-12 Globeimmune, Inc. composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta
RU2017143985A (ru) 2011-08-17 2019-02-14 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения
US20130216589A1 (en) * 2012-02-17 2013-08-22 Rich Content Biotech INC. Oral vaccine for aquatic animals
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
EP2864792A1 (en) 2012-06-26 2015-04-29 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
WO2014049604A2 (en) * 2012-09-05 2014-04-03 Amrita Therapeutics Limited A novel biomedical device for cancer therapy
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
SI2968529T1 (sl) 2013-03-14 2021-03-31 Aimmune Therapeutics, Inc. Izdelava arašidovih formulacij arašida za ustno desenzibilizacijo
WO2014186047A1 (en) 2013-03-19 2014-11-20 Globeimmune, Inc. Yeast-based immunotherapy for chordoma
WO2014160747A2 (en) 2013-03-26 2014-10-02 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
EP3760223A1 (en) 2013-04-03 2021-01-06 N-Fold Llc Nanoparticle composition for desensitizing a subject to peanut allergens
TWI654200B (zh) 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
AU2015241380B2 (en) 2014-04-03 2020-11-26 AllerGenis LLC Peptides, reagents and methods for detecting food allergy
KR102409372B1 (ko) 2014-04-11 2022-06-16 글로브이뮨 효모 면역 요법 및 타입 i 인터페론 감도
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017023840A1 (en) 2015-08-03 2017-02-09 Globeimmune, Inc. Modified yeast-brachyury immunotherapeutic compositions
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CA3080253A1 (en) * 2017-10-25 2019-05-02 Allero Therapeutics Bv Treatment of immune diseases by administration of antigen-specific formulations
CA3080601A1 (en) 2017-11-02 2019-05-09 Aimmune Therapeutics, Inc. Methods of oral immunotherapy
CN119818663A (zh) 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
EP3836801A4 (en) 2018-08-16 2022-05-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
CN113891722A (zh) 2018-12-20 2022-01-04 爱沐疗法公司 用于漏服剂量的花生口服免疫疗法给药计划表
EP3965815A4 (en) 2019-05-10 2023-05-31 Société des Produits Nestlé S.A. METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT
US20210247404A1 (en) * 2020-02-06 2021-08-12 AllerGenis LLC Assays For Detecting Peanut Allergies
WO2025212530A1 (en) 2024-04-01 2025-10-09 N-Fold Llc Nanoparticle manufacturing

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US588799A (en) * 1897-08-24 Mechanism
US3097141A (en) * 1959-02-26 1963-07-09 Kidwell Elizabeth N Wilcox Immunological method
SE337223B (enExample) 1967-05-23 1971-08-02 Pharmacia Ab
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US4171299A (en) 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4338297A (en) 1980-02-19 1982-07-06 Michael Jacob G Polypeptide active pollen immunosuppressant fraction
US4469677A (en) 1980-02-19 1984-09-04 Michael J Gabriel Polypeptide active immunosuppressant fraction
FI76888C (fi) 1981-04-29 1988-12-12 Ciba Geigy Ag Nya medel och foerpackningar foer immunologiska analyser.
CA1338705C (en) * 1981-10-22 1996-11-12 Roy Curtiss Iii Vaccines obtained from antigenic gene products of recombinant genes
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
SE8205908D0 (sv) 1982-10-18 1982-10-18 Pharmacia Diagnostics Ab Sett att bilda polymerskikt
US4849337A (en) 1983-01-31 1989-07-18 Minnesota Mining And Manufacturing Company Assaying allergen specific IgE levels with fluorogenic enzyme labeled antibody
CA1260828A (en) * 1983-07-04 1989-09-26 Masakazu Iwai Therapeutic and prophylactic agent for gastrointestinal ulcers
US4816449A (en) 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents
US4579840A (en) 1983-08-12 1986-04-01 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin Fc receptors
US4680174A (en) 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US4696915A (en) 1984-05-25 1987-09-29 Hoffmann-La Roche Inc. Parathymosin alpha
US5026545A (en) 1984-09-17 1991-06-25 Baxter International, Inc. Treatment of allergy and composition therefor
US4658022A (en) * 1985-08-08 1987-04-14 Molecular Diagnostics, Inc. Binding of antibody reagents to denatured protein analytes
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4900556A (en) 1985-04-26 1990-02-13 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5843710A (en) 1987-07-07 1998-12-01 Biotech Australia Pty. Limited And Csiro Vaccines against animal parasitic nematodes
US5049390A (en) 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
AT393137B (de) 1988-10-14 1991-08-26 Biomay Biotech Prod Verfahren zum screenen einer expressions-cdna- klonbank zur auffindung von polynukleotiden
US5061790A (en) * 1989-07-10 1991-10-29 Molecular Diagnostics, Inc. Oxidative denaturation of protein analytes
JP2787162B2 (ja) 1989-08-24 1998-08-13 フマキラー株式会社 精製ダニアレルゲン
US5834246A (en) * 1989-09-18 1998-11-10 Vitec Aktiebolag Recombinant systems for expression of cholera B-subunit with the aid of foreign promoters and/or leader peptides
US5547669A (en) * 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
US5328991A (en) * 1989-11-03 1994-07-12 Immulogic Pharmaceutical Corp. Preparation of alkali-modified cat dander allergen (Fel d I) for immunotherapeutic purposes
US6019972A (en) * 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
AU650249B2 (en) 1989-11-03 1994-06-16 Immulogic Pharmaceutical Corporation A human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
AU7259691A (en) 1990-01-31 1991-08-21 Board Of Regents Of The University Of Oklahoma, The Assays and treatments for autoimmune diseases
US6897287B1 (en) 1990-01-31 2005-05-24 Oklahoma Medical Research Foundation Ro/SSA peptide reagents for diagnosis of autoantibodies
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5091318A (en) 1990-04-13 1992-02-25 Abbott Laboratories Binding of allergens to a solid phase
US5888762A (en) 1990-06-05 1999-03-30 Centre National De La Recherche Scientifique (Cnrs) Neurotropic growth factors comprising a homeobox peptide
WO1992002621A2 (en) 1990-08-08 1992-02-20 Biomay Biotechnik Produktions- Und Handelsgesellschaft M.B.H. Allergens of alder pollen and applications thereof
AT401180B (de) 1990-08-13 1996-07-25 Biomay Biotech Prod Für das baumpollenallergen p14 codierende rekombinante dna-moleküle, daraus hergestellte und abgeleitete polypeptide und deren verwendung
WO1992003551A1 (en) 1990-08-13 1992-03-05 Biomay Biotechnik Produktions- Und Handelsgesellschaft M.B.H. Birch pollen allergen p14 for diagnosis and therapy of allergic diseases
JP3139777B2 (ja) 1990-08-27 2001-03-05 フマキラー株式会社 組換えダニアレルゲン
KR950008087B1 (ko) 1990-09-17 1995-07-25 미쓰이세끼유 가가꾸고오교오 가부시끼가이샤 폴리카보네이트, 그 용도, 그 제조방법 및 정제방법
US5599537A (en) 1990-12-18 1997-02-04 The General Hospital Corporation Salmonella virulence genes
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
US5350835A (en) 1991-11-05 1994-09-27 Board Of Regents, University Of Texas Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
JP3156237B2 (ja) 1991-12-24 2001-04-16 雪印乳業株式会社 抗ヒトＩｇＥ モノクローナル抗体
GB2278358B (en) * 1992-02-27 1995-07-26 Lynxvale Ltd Heterologous gene expression in Lactococcus,and the expression products therefrom
US5480972A (en) 1992-10-30 1996-01-02 The University Of Melbourne Allergenic proteins from Johnson grass pollen
ES2095001T5 (es) 1992-12-22 2001-03-16 Univ Cincinnati Una composicion terapeutica administrable oralmente y su metodo de obtencion.
US5558869A (en) 1992-12-30 1996-09-24 University Of Arkansas Major peanut allergen ara h II
US5939283A (en) 1992-12-31 1999-08-17 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from dog dander and uses therefor
ES2114184T3 (es) 1993-02-12 1998-05-16 Mayo Foundation Composicion a base de microparticulas en fase condensada y procedimiento.
WO1994019482A1 (en) 1993-02-22 1994-09-01 The General Hospital Corporation Heterologous antigens in live cell vaccine strains
JP3451572B2 (ja) 1993-03-04 2003-09-29 アサヒビール株式会社 改変したダニ主要アレルゲン及びその製造方法
FI954269A0 (fi) 1993-03-12 1995-09-12 Immunologic Pharma Corp Raiheinäsiitepölyallergeenin T-soluepitoopit
US5710126A (en) 1993-03-12 1998-01-20 Immulogic Pharmaceutical Corporation T cell epitopes of ryegrass pollen allergen
US6849427B1 (en) 1993-03-12 2005-02-01 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p VII, and uses therefor
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
JP3350794B2 (ja) 1993-09-29 2002-11-25 アサヒビール株式会社 改変したダニ主要アレルゲン
JP2828391B2 (ja) * 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
US5449669A (en) 1993-11-10 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services IgE-binding epitopes of a major heat-stable crustacean allergen derived from shrimp
US5731157A (en) 1993-12-30 1998-03-24 The Procter And Gamble Company Two-site allergen immunoassay
US5820862A (en) 1994-04-14 1998-10-13 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
JPH07285875A (ja) 1994-04-19 1995-10-31 Mineo Hayazaki ノミアレルゲンの製造方法および該方法により製造されるノミアレルゲン
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
SE9402089D0 (sv) 1994-06-14 1994-06-14 Rudolf Valenta Recombinant allergen, fragments thereof, corresponding recombinant DNA molecules, vectors and hosts containing the DNA molecules, diagnostic and therapeutic uses of said allergens and fragments
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0819763B1 (en) 1995-03-28 2004-11-17 Asahi Breweries, Ltd. Engineered acarid allergen and process for producing the same
US5840307A (en) 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US5820880A (en) * 1995-06-07 1998-10-13 The United States Of America As Represented By The Secretary Of The Army Liposomal formulation
US5869040A (en) 1995-06-07 1999-02-09 Biogen, Inc Gene therapy methods and compositions
US20030202980A1 (en) * 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
JPH11507840A (ja) * 1995-12-29 1999-07-13 ユニバーシティ オブ アーカンソー ピーナッツアレルゲンおよび方法
US5955593A (en) 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
SE9604815D0 (sv) * 1996-12-20 1996-12-20 Pharmacia & Upjohn Ab A metod of diagnosis
EP0973881A2 (en) * 1997-03-28 2000-01-26 Cytoclonal Pharmaceutics Inc. Mycobacterium recombinant vaccines
US5989814A (en) 1997-04-01 1999-11-23 Reagents Of The University Of California Screening methods in eucaryotic cells
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
DE69738124T2 (de) 1997-05-08 2008-06-12 Amarnath Maitra Verfahren zur Herstellung von hochmonodisperser, Polymeren, hydrophiler Nanopartikel
DE19729327C1 (de) * 1997-07-09 1998-10-29 Wieland Electric Gmbh Schutzleiterklemme
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US6024961A (en) * 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
DE69940805D1 (de) * 1998-01-31 2009-06-10 Sinai School Medicine Verfahren und reagenzien zur verminderung der klinischen reaktion zur allergie
ES2284247T3 (es) * 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
US6270723B1 (en) * 1998-06-15 2001-08-07 Bbi Bioseq, Inc. Rapid cryobaric sterilization and vaccine preparation
AU748565B2 (en) * 1998-06-23 2002-06-06 Board Of Trustees Of The Leland Stanford Junior University Adjuvant therapy
US6004815A (en) * 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
JP2000210050A (ja) * 1998-11-20 2000-08-02 Asama Kasei Kk 免疫調節活性分解物およびその製造方法並びにそれを用いた食品
AU3760100A (en) * 1999-03-16 2000-10-04 Panacea Pharmaceuticals, Llc Immunostimulatory nucleic acids and antigens
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
ES2260078T3 (es) * 2000-04-06 2006-11-01 Seer Pharmaceuticals, Llc. Sistema de administracion microbiana.
US20050063994A1 (en) * 2000-04-06 2005-03-24 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
DE60032250T2 (de) * 2000-12-28 2007-03-15 Biomay Produktions- Und Handels-Aktiengesellschaft Behandlung von Allergien
US7265208B2 (en) * 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof

Also Published As

Publication number Publication date
CA2403292A1 (en) 2001-09-13
EP1272213A2 (en) 2003-01-08
AU1951001A (en) 2001-09-17
US20130243814A1 (en) 2013-09-19
US20040208894A1 (en) 2004-10-21
US20110027298A1 (en) 2011-02-03
DE60026584D1 (de) 2006-05-04
US8153414B2 (en) 2012-04-10
US20030035810A1 (en) 2003-02-20
DK1272213T3 (da) 2006-07-10
US8815251B2 (en) 2014-08-26
DE60026584T2 (de) 2007-03-08
ES2260078T3 (es) 2006-11-01
JP2012207032A (ja) 2012-10-25
WO2001066136A3 (en) 2001-12-27
CA2403292C (en) 2011-02-08
US20040234548A1 (en) 2004-11-25
EP1272213B1 (en) 2006-03-08
US20130142817A1 (en) 2013-06-06
WO2001066136A2 (en) 2001-09-13
JP2004527450A (ja) 2004-09-09
JP2009242427A (ja) 2009-10-22
CY1105216T1 (el) 2010-03-03
AU2001219510B2 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
ATE319475T1 (de) Microbielles wirkstoffabgabesystem
Powers et al. Microbiome and pediatric atopic dermatitis
Ryan et al. Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens
CY1110727T1 (el) Παρασκευασματα θετικων κατα gram βακτηριων για τη θεραπεια ασθενειων που περιλαμβανουν μια ανοσολογικη δυσρυθμιση
Tang et al. Oral immunotherapy and tolerance induction in childhood
WO2004087203A3 (en) Immunostimulatory nucleic acid oil-in-water formulations for topical application
Pfaar et al. Ultra‐short‐course booster is effective in recurrent grass pollen‐induced allergic rhinoconjunctivitis
Sharquie BCG is a good immunotherapeutic agent for viral and autoimmune diseases: is it a new weapon against coronavirus (COVID-19)?
Horner Toll-like receptor ligands and atopy: a coin with at least two sides
Hughes et al. Masked delivery of allergen in nanoparticles safely attenuates anaphylactic response in murine models of peanut allergy
EP4295862A3 (en) Coronavirus vaccine
Pichler et al. The fold variant BM4 is beneficial in a therapeutic Bet v 1 mouse model
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
EP2174665A3 (en) Compositions and methods for activating innate and allergic immunity
WO2007053176A3 (en) Method of protecting against staphylococcal infection
Sánchez-Ramón et al. Extending the clinical horizons of mucosal bacterial vaccines: current evidence and future prospects
Kim et al. Infection, allergy and the hygiene hypothesis: historical perspective
WO2001049319A8 (de) Zusammensetzung, enthaltend bakterielle antigene, zum vorbeugen und behandeln von allergischen erkrankungen
Repa et al. Susceptibility to nasal and oral tolerance induction to the major birch pollen allergen Bet v 1 is not dependent on the presence of the microflora
BR0201889A (pt) Vacinas de ige não-anafilactogênicas
Grüber et al. Common vaccine antigens inhibit allergen‐induced sensitization and airway hyperresponsiveness in a murine model
WO2004045556A3 (en) Methods for inhibiting allergic inflammation and other responses initiated by pollens, molds, and other non-animal derived allergens
Moritz Vaccine-nation: Poisoning the population, one shot at a time
Zroog et al. Common side effects of Johnson and Johnson COVID-19 vaccine in Ruffaa city, Gezira, Sudan January (2022)
Sim Food Allergies: A Growing Public Health Crisis and the Path to Solutions

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1272213

Country of ref document: EP